J Chabot - Concepedia

Concepedia

Author

J Chabot

Pfizer (United States)

Also Known As

Chabot, Jeffrey R., J CHABOT, J Chabot, J R Chabot, J. CHABOT, J. Chabot, J. R. Chabot, J. Richard Chabot, J.R. Chabot, J.Richard Chabot

63

Publications

2.1K

Citations

18

H-Index

73

Concepts

All Affiliations

Pfizer (United States)Baystate Medical Center Tufts University Massachusetts Institute of Technology

JC

About

J Chabot is an author at Pfizer (United States) specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1K
2	Health Sciences	3	3	593
3	Natural Sciences	3	3	190
4	Engineering	2	2	202
5	Behavioral Sciences	1	1	32

J Chabot

×

23

Publications

2.1K

Citations

18

H-Index

	Year	Citations
Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury Jinghai J. Xu, Peter Henstock, Margaret C. Dunn, Toxicological Sciences	2008	485
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects Saswata Talukdar, Yingjiang Zhou, Dongmei Li, Cell Metabolism ObesityMetabolic SyndromeLong-acting Fgf21 MoleculeGrowth HormoneMetabolic Disorder	2016	477
Probing polymerization forces by using actin-propelled lipid vesicles Arpita Upadhyaya, J Chabot, A P Andreeva, Proceedings of the National Academy of Sciences Membrane StructureOsmotic PressurePolymerization ForcesMembrane BiophysicsEngineering	2003	191
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 Javier Chaparro‐Riggers, Liang Hong, Rachel M. DeVay, Journal of Biological Chemistry	2012	164
Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates Albert M. Kim, Veena Somayaji, Jennifer Dong, Diabetes Obesity and Metabolism	2017	136
Stochastic gene expression out-of-steady-state in the cyanobacterial circadian clock J Chabot, Juan Manuel Pedraza, Prashant Luitel, Nature BiologySystems BiologyAlertnessMedicineNatural Sciences	2007	115
Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice Yan Weng, J Chabot, Barbara Bernardo, PLoS ONE Fgf21 AnalogsMetabolic DisorderIntact Fgf21 C-terminusMetabolic RemodelingPhysiologically-based Pharmacokinetic Modeling	2015	67
Survival following moderate-dose preoperative radiation therapy for carcinoma of the rectum Paul Friedmann, Jane Garb, Won C. Park, Cancer Radiation MedicineSurgical OncologyRadiation PatientsRadiation TherapyMedicine	1985	49
Liver‐Targeted Small‐Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis Kim F. McClure, David W. Piotrowski, Donna N. Petersen, Angewandte Chemie International Edition	2017	45
Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities Vahid Farrokhi, J Chabot, Hendrik Neubert, Scientific Reports SclerostinOsteopathyImmunologyBone RepairOsteoporosis	2018	45

Page 1